Acceptability and cost-effectiveness of blood sample transport by drone for HIV-testing of infants exposed to HIV in the city of Conakry, Guinea (ANRS 12407 AIRPOP) by Maxime Inghels (17160577)

Typical snapshots of strategy distributions on the square lattice when <i>σ</i> = 0.5 and <i>r</i> = 5. by Keke Huang (703621)

Table 5_Interaction with IGF1 overrides ANXA2-mediated anti-inflammatory functions of IGFBP5 in vivo.docx by Yan Fan (575147)

“…Background<p>IGFBP5 is a differentially expressed gene (DEG) between M1 and M2 macrophages. …”

Image_5_Autophagy Induced Accumulation of Lipids in pgrl1 and pgr5 of Chlamydomonas reinhardtii Under High Light.TIF by Nisha Chouhan (11994860)

“…<p>Chlamydomonas (C.) reinhardtii is a potential microalga for lipid production. Autophagy-triggered lipid metabolism in microalgae has not being studied so far from a mutant of proton gradient regulation 1 like (PGRL1) and proton gradient regulation 5 (PGR5). …”

BMD analysis of serum free T4 (A), serum free T3 (B) and serum TSH (C) in males (triangles) and females (circles). by Matti Viluksela (321291)

“…Small symbols indicate individual samples, large symbols the group mean; the vertical dotted line indicates the dose (CED) with 5% decrease or increase (CES -0.05) compared to background (a parameter). …”

Table_1_Investigating the Added Value of the EQ-5D-5L With Two Bolt-On Items in Patients With Hemophilia.DOCX by Richard Huan Xu (7901480)

“…Spearman's rank correlation (rho) was used to assess the associations of the EQ-5D-5L and two bolt-on items with the Hemophilia Quality of Life Questionnaire for Adults (Haem-A-QoL) and SF-12. …”

Sankey diagram showing an overview of the dynamic shifts of the 5 risk groups from day 0 to day 14 after admission. by Guiyou Yang (10259597)

Design of a RSSCA system for agriculture. by Ngoc-Hai Vu (22290844)

“…<div><p>Agricultural land is increasingly under pressure from expanding solar energy infrastructure, leading to a growing conflict between food and energy production. …”

ERK5-RNA interference suppresses MCF-7-MEK5 tumor growth and restores ER-α protein expression. by James W. Antoon (444010)

“…Decreased expression of ERK5 was confirmed with (A) RT-PCR and (B) western blot analysis. …”

Ybx1 regulation of its target mRNAs is m⁵C-depdendent (Related to Fig 5). by Jian Zhang (1682)

“…<p><b>(A)</b> RT-qPCR confirmed the decreased expression levels of Ybx1 target mRNAs in neural stem cells with Ybx1 knockdown using siRNA. …”

Image_2_Upregulated IL-6 Indicates a Poor COVID-19 Prognosis: A Call for Tocilizumab and Convalescent Plasma Treatment.TIF by Jian Wu (41301)

“…As a stable indicator, the changes in IL-6 levels could indicate the inflammatory conditions during a viral infection. …”

Image_6_Upregulated IL-6 Indicates a Poor COVID-19 Prognosis: A Call for Tocilizumab and Convalescent Plasma Treatment.TIF by Jian Wu (41301)

“…As a stable indicator, the changes in IL-6 levels could indicate the inflammatory conditions during a viral infection. …”

Image_1_Upregulated IL-6 Indicates a Poor COVID-19 Prognosis: A Call for Tocilizumab and Convalescent Plasma Treatment.TIF by Jian Wu (41301)

“…As a stable indicator, the changes in IL-6 levels could indicate the inflammatory conditions during a viral infection. …”

Image_3_Upregulated IL-6 Indicates a Poor COVID-19 Prognosis: A Call for Tocilizumab and Convalescent Plasma Treatment.TIF by Jian Wu (41301)

“…As a stable indicator, the changes in IL-6 levels could indicate the inflammatory conditions during a viral infection. …”

Image_4_Upregulated IL-6 Indicates a Poor COVID-19 Prognosis: A Call for Tocilizumab and Convalescent Plasma Treatment.TIFF by Jian Wu (41301)

“…As a stable indicator, the changes in IL-6 levels could indicate the inflammatory conditions during a viral infection. …”

Cofactors required for Vpu activities. by Charlotte A. Stoneham (10819125)

List of Included studies. by Zahra Tajik (20752452)

“…The results show that one month after the NSPT, there was no significant difference in the mean visfatin level of GCF (SMD: -3.91, 95%CI: -9.83, 2.01, p = 0.195, I-square, 96.6%, random effect model, n = 2) and serum (SMD: -0.33, 95%CI: -0.98, 0.33, p = 0.332, fixed effect model, n = 1), but 2, 3 and 6 months after NSPT, the mean visfatin level of GCF and serum decreased significantly. There is no significant difference one month after NSPT in diabetic patients (SMD: -5.83, 95%CI: -15.5, 3.83, p = 0.237, I-square, 97.4%, random effects model, n = 2), but three (SMD: -2.44, 95%CI: -3.37, -1.15, p = 0.001, I-square, 75.9%, random effects model, n = 3) and six months (SMD: -2.41, 95%CI: -3.81, -1.01, p = 0.001, I-square, 78.7%, random effects model, n = 2) after the treatment, a significant decrease is observed in the mean GCF visfatin level. …”

The search strategy in three databases. by Zahra Tajik (20752452)

“…The results show that one month after the NSPT, there was no significant difference in the mean visfatin level of GCF (SMD: -3.91, 95%CI: -9.83, 2.01, p = 0.195, I-square, 96.6%, random effect model, n = 2) and serum (SMD: -0.33, 95%CI: -0.98, 0.33, p = 0.332, fixed effect model, n = 1), but 2, 3 and 6 months after NSPT, the mean visfatin level of GCF and serum decreased significantly. There is no significant difference one month after NSPT in diabetic patients (SMD: -5.83, 95%CI: -15.5, 3.83, p = 0.237, I-square, 97.4%, random effects model, n = 2), but three (SMD: -2.44, 95%CI: -3.37, -1.15, p = 0.001, I-square, 75.9%, random effects model, n = 3) and six months (SMD: -2.41, 95%CI: -3.81, -1.01, p = 0.001, I-square, 78.7%, random effects model, n = 2) after the treatment, a significant decrease is observed in the mean GCF visfatin level. …”

NIH score. by Zahra Tajik (20752452)

“…The results show that one month after the NSPT, there was no significant difference in the mean visfatin level of GCF (SMD: -3.91, 95%CI: -9.83, 2.01, p = 0.195, I-square, 96.6%, random effect model, n = 2) and serum (SMD: -0.33, 95%CI: -0.98, 0.33, p = 0.332, fixed effect model, n = 1), but 2, 3 and 6 months after NSPT, the mean visfatin level of GCF and serum decreased significantly. There is no significant difference one month after NSPT in diabetic patients (SMD: -5.83, 95%CI: -15.5, 3.83, p = 0.237, I-square, 97.4%, random effects model, n = 2), but three (SMD: -2.44, 95%CI: -3.37, -1.15, p = 0.001, I-square, 75.9%, random effects model, n = 3) and six months (SMD: -2.41, 95%CI: -3.81, -1.01, p = 0.001, I-square, 78.7%, random effects model, n = 2) after the treatment, a significant decrease is observed in the mean GCF visfatin level. …”

List of excluded studies. by Zahra Tajik (20752452)

“…The results show that one month after the NSPT, there was no significant difference in the mean visfatin level of GCF (SMD: -3.91, 95%CI: -9.83, 2.01, p = 0.195, I-square, 96.6%, random effect model, n = 2) and serum (SMD: -0.33, 95%CI: -0.98, 0.33, p = 0.332, fixed effect model, n = 1), but 2, 3 and 6 months after NSPT, the mean visfatin level of GCF and serum decreased significantly. There is no significant difference one month after NSPT in diabetic patients (SMD: -5.83, 95%CI: -15.5, 3.83, p = 0.237, I-square, 97.4%, random effects model, n = 2), but three (SMD: -2.44, 95%CI: -3.37, -1.15, p = 0.001, I-square, 75.9%, random effects model, n = 3) and six months (SMD: -2.41, 95%CI: -3.81, -1.01, p = 0.001, I-square, 78.7%, random effects model, n = 2) after the treatment, a significant decrease is observed in the mean GCF visfatin level. …”